169 related articles for article (PubMed ID: 24854489)
1. Silencing of UCHL1 by CpG promoter hyper-methylation is associated with metastatic gastroenteropancreatic well-differentiated neuroendocrine (carcinoid) tumors.
Kleiman DA; Beninato T; Sultan S; Crowley MJ; Finnerty B; Kumar R; Panarelli NC; Liu YF; Lieberman MD; Seandel M; Evans T; Elemento O; Zarnegar R; Fahey TJ
Ann Surg Oncol; 2014 Dec; 21 Suppl 4(0 4):S672-9. PubMed ID: 24854489
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors.
Yu J; Tao Q; Cheung KF; Jin H; Poon FF; Wang X; Li H; Cheng YY; Röcken C; Ebert MP; Chan AT; Sung JJ
Hepatology; 2008 Aug; 48(2):508-18. PubMed ID: 18666234
[TBL] [Abstract][Full Text] [Related]
3. Frequent CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in sporadic and hereditary Tunisian breast cancer patients: clinical significance.
Trifa F; Karray-Chouayekh S; Jmaa ZB; Jmal E; Khabir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
Med Oncol; 2013 Mar; 30(1):418. PubMed ID: 23315218
[TBL] [Abstract][Full Text] [Related]
4. Decreased UCHL1 expression as a cytologic biomarker for aggressive behavior in pancreatic neuroendocrine tumors.
Moore MD; Finnerty B; Gray KD; Hoda R; Liu YF; Soong L; Beninato T; Rao R; Zarnegar R; Fahey TJ
Surgery; 2018 Jan; 163(1):226-231. PubMed ID: 29150024
[TBL] [Abstract][Full Text] [Related]
5. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.
Miller HC; Drymousis P; Flora R; Goldin R; Spalding D; Frilling A
World J Surg; 2014 Jun; 38(6):1353-61. PubMed ID: 24493070
[TBL] [Abstract][Full Text] [Related]
6. UCHL1 loss alters the cell-cycle in metastatic pancreatic neuroendocrine tumors.
Finnerty BM; Moore MD; Verma A; Aronova A; Huang S; Edwards DP; Chen Z; Seandel M; Scognamiglio T; Du YN; Elemento O; Zarnegar R; Min IM; Fahey TJ
Endocr Relat Cancer; 2019 Apr; 26(4):411-423. PubMed ID: 30689542
[TBL] [Abstract][Full Text] [Related]
7. Cancer detection by ubiquitin carboxyl-terminal esterase L1 methylation in pancreatobiliary fluids.
Kato N; Yamamoto H; Adachi Y; Ohashi H; Taniguchi H; Suzuki H; Nakazawa M; Kaneto H; Sasaki S; Imai K; Shinomura Y
World J Gastroenterol; 2013 Mar; 19(11):1718-27. PubMed ID: 23555160
[TBL] [Abstract][Full Text] [Related]
8. CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma.
Kagara I; Enokida H; Kawakami K; Matsuda R; Toki K; Nishimura H; Chiyomaru T; Tatarano S; Itesako T; Kawamoto K; Nishiyama K; Seki N; Nakagawa M
J Urol; 2008 Jul; 180(1):343-51. PubMed ID: 18499164
[TBL] [Abstract][Full Text] [Related]
9. Prognoses of GEP-NETS with undetermined malignant potentials of their primary sites.
Kudo A; Ban D; Akashi T; Kumagai J; Aihara A; Inokuchi M; Kojima K; Kawano T; Tanaka S; Arii S
Hepatogastroenterology; 2012 Sep; 59(118):1682-6. PubMed ID: 22584425
[TBL] [Abstract][Full Text] [Related]
10. The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer.
Xiang T; Li L; Yin X; Yuan C; Tan C; Su X; Xiong L; Putti TC; Oberst M; Kelly K; Ren G; Tao Q
PLoS One; 2012; 7(1):e29783. PubMed ID: 22279545
[TBL] [Abstract][Full Text] [Related]
11. CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) and P53 mutation pattern in sporadic colorectal cancer.
Abdelmaksoud-Dammak R; Saadallah-Kallel A; Miladi-Abdennadher I; Ayedi L; Khabir A; Sallemi-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
Tumour Biol; 2016 Feb; 37(2):1707-14. PubMed ID: 26314856
[TBL] [Abstract][Full Text] [Related]
12. [The role of hypermethylation in promoter region of ubiquitin carboxyl-terminal hydrolase L1 in human esophageal cancer].
Yan WJ; Guo MZ; Yang YS
Zhonghua Nei Ke Za Zhi; 2012 May; 51(5):390-3. PubMed ID: 22883340
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation.
Ummanni R; Jost E; Braig M; Lohmann F; Mundt F; Barett C; Schlomm T; Sauter G; Senff T; Bokemeyer C; Sültmann H; Meyer-Schwesinger C; Brümmendorf TH; Balabanov S
Mol Cancer; 2011 Oct; 10():129. PubMed ID: 21999842
[TBL] [Abstract][Full Text] [Related]
14. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
15. Silencing of the UCHL1 gene in giant cell tumors of bone.
Fellenberg J; Lehner B; Witte D
Int J Cancer; 2010 Oct; 127(8):1804-12. PubMed ID: 20104524
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma.
Seliger B; Handke D; Schabel E; Bukur J; Lichtenfels R; Dammann R
J Transl Med; 2009 Oct; 7():90. PubMed ID: 19857250
[TBL] [Abstract][Full Text] [Related]
17. Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM gene.
Lee J; Sung CO; Lee EJ; Do IG; Kim HC; Yoon SH; Lee WY; Chun HK; Kim KM; Park YS
PLoS One; 2012; 7(4):e34456. PubMed ID: 22485171
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.
Özaslan E; Demir S; Karaca H; Güven K
Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127
[TBL] [Abstract][Full Text] [Related]
19. Identification of methylation-silenced genes in colorectal cancer cell lines: genomic screening using oligonucleotide arrays.
Fukutomi S; Seki N; Koda K; Miyazaki M
Scand J Gastroenterol; 2007 Dec; 42(12):1486-94. PubMed ID: 17994469
[TBL] [Abstract][Full Text] [Related]
20. Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices.
Rekhtman N; Desmeules P; Litvak AM; Pietanza MC; Santos-Zabala ML; Ni A; Montecalvo J; Chang JC; Beras A; Preeshagul IR; Sabari JK; Rudin CM; Ladanyi M; Klimstra DS; Travis WD; Lai WC
Mod Pathol; 2019 Jul; 32(8):1106-1122. PubMed ID: 30923345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
